Biktarvy is the most prescribed HIV treatment in the world, but it is not the only option — and for some patients it may not be the best one. Whether you are newly diagnosed and exploring first-line choices, experiencing side effects, facing cost barriers, or simply asking whether a switch makes clinical sense, understanding the available alternatives is a reasonable and important conversation to have with your HIV clinician.
This page compares the main guideline-recommended Biktarvy alternatives, including what is available as a licensed generic in India, pricing, key clinical differences, and the questions you should ask your clinician before any switch.
This is not switching guidance. Antiretroviral therapy decisions must be made with your HIV clinician. This page provides clinical context to inform that conversation — it does not constitute medical advice and does not replace a consultation with your prescriber.
Why Patients Consider Biktarvy Alternatives
Most patients on Biktarvy who are virologically suppressed have no clinical reason to switch. The regimen’s efficacy, tolerability, and high resistance barrier make it a strong long-term option. Common reasons patients and clinicians explore alternatives include:
- Cost: Brand Biktarvy is $4,216/month in the US. Generic B/F/TAF from India is $150/month. Generic dolutegravir-based alternatives may cost less.
- Side effects: Some patients experience insomnia, vivid dreams, or weight changes on integrase inhibitor-based regimens and explore alternatives.
- Simplification: Patients with strong adherence records sometimes switch to a two-drug regimen such as Dovato to reduce pill burden or long-term drug exposure.
- Comorbidities: Renal impairment, bone density concerns, or cardiovascular risk factors can influence regimen selection.
- Hepatitis B coinfection: Biktarvy is active against HBV due to its emtricitabine and TAF components. Any switch for an HBV-coinfected patient must include agents active against HBV.
- Drug interactions: Biktarvy interacts with antacids, certain supplements, and rifampicin. Patients on complex polypharmacy may need an interaction review.
The Main Biktarvy Alternatives
Dovato is a two-drug regimen (2DR) combining dolutegravir (an integrase inhibitor) and lamivudine (an NRTI). It achieves viral suppression rates comparable to three-drug regimens in treatment-naïve patients with baseline viral loads below 500,000 copies/mL, as demonstrated in the GEMINI-1 and GEMINI-2 phase 3 trials. The two-drug backbone means less long-term drug exposure compared to a three-drug regimen.
Not suitable for: patients with hepatitis B coinfection (lamivudine alone is insufficient for HBV); patients with HIV RNA ≥500,000 copies/mL at baseline; patients with suspected or confirmed lamivudine or integrase resistance.
Generic dolutegravir/lamivudine is available from Indian manufacturers under MPP licence, typically priced around $60–$90 per month.
Triumeq is a three-drug regimen built around dolutegravir with abacavir and lamivudine as the NRTI backbone. It has a strong efficacy and tolerability record across a broad patient population. Dolutegravir’s resistance barrier is high — comparable to bictegravir — and treatment-emergent resistance to dolutegravir in clinical trials has been rare.
Important: HLA-B*5701 testing is required before prescribing abacavir. Approximately 5–8% of white patients carry the HLA-B*5701 allele associated with abacavir hypersensitivity syndrome (AHS), which can be severe or fatal. Patients who test positive must not receive abacavir.
Triumeq may be less preferred in patients with cardiovascular risk factors, as some observational studies have suggested a potential association between abacavir use and cardiovascular events, though the evidence remains debated.
Generic abacavir/dolutegravir/lamivudine is available from Indian manufacturers, typically priced around $70–$95 per month.
Symtuza is a protease inhibitor (PI)-based regimen using darunavir boosted by cobicistat. It is generally reserved for situations where integrase inhibitors are not appropriate or preferred — such as patients with documented integrase resistance — or where a protease inhibitor backbone is clinically indicated. Darunavir has a high genetic barrier to resistance and is a preferred PI option across treatment guidelines.
Cobicistat is a pharmacokinetic booster that has significant drug interaction potential. Patients on Symtuza require a thorough drug interaction review before starting. Cobicistat also affects serum creatinine measurements (a functional effect, not actual renal toxicity), which must be noted when interpreting renal function results.
Symtuza is not as commonly prescribed as integrase inhibitor-based regimens for treatment-naïve patients. Generic darunavir and cobicistat-based combinations have more limited availability in India compared to dolutegravir-based options.
Juluca is a two-drug switch regimen combining dolutegravir with rilpivirine. It is indicated for virologically suppressed adults who are switching from a stable regimen — not for treatment-naïve patients. The SWORD-1 and SWORD-2 trials demonstrated non-inferior viral suppression rates in suppressed patients switching to Juluca versus continuing three-drug regimens.
Restrictions apply: Juluca requires no prior virological failure or documented resistance to either dolutegravir or rilpivirine, no current or anticipated use of proton pump inhibitors (which reduce rilpivirine absorption), and must be taken with a substantial meal (≥500 kcal). Rilpivirine is associated with depression and insomnia in some patients.
Generic dolutegravir/rilpivirine combinations from India have limited availability and are not as widely used as dolutegravir/lamivudine generics.
Delstrigo is an NNRTI-based three-drug regimen built around doravirine, a newer NNRTI with a favourable resistance profile compared to older agents like efavirenz. It is associated with less CNS toxicity than efavirenz and has a flat effect on lipids. Doravirine has moderate resistance barrier — lower than dolutegravir or bictegravir — and is contraindicated with rifampicin.
Delstrigo uses tenofovir disoproxil fumarate (TDF) rather than TAF. TDF has a higher plasma tenofovir exposure and greater renal tubular and bone effects than TAF. It should be used with caution in patients with or at risk of renal impairment or low bone mineral density.
Generic doravirine-based combinations from India have limited availability. Doravirine is a relatively newer molecule and generic licences are less established than for dolutegravir-based regimens.
Side-by-Side Clinical Comparison
| Regimen | Drugs | Class | Resistance Barrier | HBV Active? | India Generic |
|---|---|---|---|---|---|
| Biktarvy | BIC/FTC/TAF | INSTI + 2 NRTIs | Very high | Yes (FTC + TAF) | Yes — ~$150/mo |
| Dovato | DTG/3TC | INSTI + NRTI (2DR) | High | No | Yes — ~$70/mo |
| Triumeq | ABC/DTG/3TC | INSTI + 2 NRTIs | High | Limited | Yes — ~$80/mo |
| Symtuza | DRV/COBI/FTC/TAF | PI/COBI + 2 NRTIs | High | Yes (FTC + TAF) | Limited |
| Juluca | DTG/RPV | INSTI + NNRTI (2DR) | Moderate–high | No | Limited |
| Delstrigo | DOR/3TC/TDF | NNRTI + 2 NRTIs | Moderate | Limited | Limited |
Which Patients May Benefit From a Switch Away From Biktarvy?
Patients Considering Dovato (DTG/3TC)
Good candidates for a switch to dolutegravir/lamivudine are virologically suppressed patients with no prior virological failure, no documented integrase or lamivudine resistance, no hepatitis B coinfection, and a desire to reduce overall drug exposure with a two-drug regimen. The TANGO trial demonstrated maintained suppression in patients switching from TDF-based regimens to Dovato.
Patients on Abacavir-Containing Regimens (Triumeq)
Patients who have already tested HLA-B*5701 negative and tolerate abacavir may have clinical reasons to remain on a dolutegravir/abacavir/lamivudine regimen. Conversely, patients at elevated cardiovascular risk and those with HLA-B*5701 positivity should not use abacavir-containing regimens.
Patients Considering a Switch for Cost Reasons
If cost is the primary driver, the choice between generic B/F/TAF (~$150/month from India) and generic DTG/3TC (~$70/month) requires clinical input. Patients with HBV coinfection cannot switch to DTG/3TC. Patients with prior lamivudine exposure or documented lamivudine resistance are not suitable for DTG/3TC. For appropriate patients, generic DTG/3TC from India offers the lowest cost among guideline-recommended options with generic availability.
Never switch antiretroviral therapy without clinician guidance. Switching between regimens without resistance history review, appropriate monitoring, and medical oversight risks virological failure and development of resistance mutations that may narrow future treatment options permanently.
Generic Availability From India: What Is Available
| Generic | Brand Equivalent | MPP Licence | Approx. India Price | Availability |
|---|---|---|---|---|
| B/F/TAF | Biktarvy | Yes (Hetero, Cipla) | ~$150/mo | Good |
| DTG/3TC | Dovato | Yes (multiple) | ~$60–70/mo | Excellent |
| ABC/DTG/3TC | Triumeq | Yes (multiple) | ~$70–95/mo | Good |
| DRV/COBI/FTC/TAF | Symtuza | Partial | Varies | Limited |
| DTG/RPV | Juluca | Limited | Varies | Limited |
| DOR/3TC/TDF | Delstrigo | Limited | Varies | Limited |
Questions to Ask Your HIV Clinician
- Do I have any documented resistance mutations that would limit my options?
- Am I coinfected with hepatitis B? (Eliminates DTG/3TC and other non-HBV-active regimens)
- Have I had my HLA-B*5701 status tested? (Required before any abacavir-containing regimen)
- What is my current eGFR and have I had any renal issues? (Affects TDF vs. TAF preference)
- What is my cardiovascular risk profile? (Relevant for abacavir-containing regimens)
- Are there any current drug interactions I should be aware of with my other medications?
- If I switch and experience virological blip, what is the protocol for re-testing and re-evaluation?
- If I switch to a generic from India, how should I monitor, and what should I do if my viral load becomes detectable?
Related Pages on Sunny Pharma
- What is the generic name for Biktarvy? Complete 2026 guide
- Biktarvy price in India 2026: licensed generic pricing explained
- How to buy licensed generic Biktarvy from India
- Biktarvy cost without insurance: every assistance program explained
- Biktarvy side effects: complete 5-year clinical data
Frequently Asked Questions
The main guideline-recommended alternatives include Dovato (dolutegravir/lamivudine), Triumeq (abacavir/dolutegravir/lamivudine), Symtuza (darunavir/cobicistat/emtricitabine/TAF), Juluca (dolutegravir/rilpivirine), and Delstrigo (doravirine/lamivudine/TDF). The right choice depends on your resistance history, comorbidities, hepatitis B status, and treatment history.
For appropriate patients, yes. Dovato (dolutegravir/lamivudine) is a guideline-preferred two-drug option for treatment-naïve patients with viral loads below 500,000 copies/mL and no hepatitis B coinfection. It achieves comparable suppression rates to three-drug regimens in trials and reduces overall drug exposure. Generic DTG/3TC from India is available at approximately $60–$70 per month. It is not suitable for patients with hepatitis B or documented lamivudine resistance.
Both are guideline-recommended three-drug regimens with high-resistance-barrier integrase inhibitors (bictegravir vs. dolutegravir). Biktarvy uses the TAF backbone with better renal and bone safety data than abacavir. Triumeq requires HLA-B*5701 testing and is less preferred in patients with cardiovascular risk factors. Generic ABC/DTG/3TC from India is available and less expensive than generic B/F/TAF.
Potentially yes, depending on your clinical profile. Generic DTG/3TC is available from India at approximately $60–$70/month — about half the cost of generic B/F/TAF. However, a switch requires clinician review of your resistance history, HBV status, and a viral load monitoring plan. Do not switch antiretroviral therapy without medical supervision.
Among guideline-recommended options, generic dolutegravir/lamivudine (Dovato equivalent) is the most affordable option available from India at approximately $60–$70 per month for appropriate patients. Generic abacavir/dolutegravir/lamivudine (Triumeq equivalent) is approximately $70–$95. Generic B/F/TAF (Biktarvy equivalent) is approximately $150. Suitability depends on your individual clinical factors.
Yes. Generic dolutegravir and dolutegravir-based combinations including DTG/3TC and ABC/DTG/3TC are available from MPP-licenced Indian manufacturers. Generic dolutegravir has been available in India longer than generic bictegravir and is produced by multiple manufacturers including Hetero Labs and Cipla.
Biktarvy itself (B/F/TAF) has favourable renal safety due to TAF’s low plasma exposure. For patients with significant chronic kidney disease, dolutegravir/lamivudine (no nephrotoxic NRTI) may also be appropriate. TDF-containing regimens (Delstrigo) are generally avoided in patients with eGFR below 50 mL/min. Consult your HIV clinician and nephrologist for personalised guidance.
Abacavir-containing regimens (Triumeq) require HLA-B*5701 testing before prescribing. Biktarvy and dolutegravir/lamivudine regimens do not. All patients starting or switching ART should have resistance testing to guide regimen selection.
Yes. All the main alternatives discussed — Dovato, Triumeq, Symtuza, Juluca, and Delstrigo — are once-daily regimens. Twice-daily regimens are generally only used in specific clinical situations such as confirmed first-generation integrase inhibitor resistance.
Patients with HIV/HBV coinfection should remain on a regimen with full HBV activity. Biktarvy (FTC + TAF) is active against both. Acceptable alternatives that maintain HBV coverage include Symtuza (FTC + TAF) and efavirenz/emtricitabine/TAF combinations. Regimens without dual HBV-active agents (such as DTG/3TC alone, ABC/DTG/3TC, or Juluca) are contraindicated in HBV coinfection. Abruptly stopping HBV-active therapy can cause severe hepatitis B flares.
Medically reviewed by Dr. Neha Mishra, MD, HIV & Infectious Disease Specialist
Written by Karen Cooksey
How we reviewed this article:
Sunny Pharma follows strict sourcing guidelines and relies on peer-reviewed clinical trial data, DHHS HIV treatment guidelines, FDA prescribing information, and Medicines Patent Pool licensing documentation. Learn more in our editorial policy.
Sources & References
- DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents — Guidelines for the Use of Antiretroviral Agents: clinicalinfo.hiv.gov
- Cahn P et al. — GEMINI-1 and GEMINI-2: Dolutegravir plus lamivudine versus dolutegravir plus tenofovir DF/emtricitabine (phase 3, 2019): PubMed
- Gallant J et al. — Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine (phase 3): The Lancet, 2017
- van Wyk J et al. — TANGO: Switching from TDF-based triple-drug regimen to DTG/3TC two-drug regimen: PubMed
- FDA — Biktarvy Prescribing Information (2025): accessdata.fda.gov
- FDA — Dovato Prescribing Information: accessdata.fda.gov
- FDA — Triumeq Prescribing Information: accessdata.fda.gov
- Medicines Patent Pool — Licences: medicinespatentpool.org
- Sunny Pharma — Biktarvy Generic Guide: sunnypharma.info
- Sunny Pharma — Buy Biktarvy Online India: sunnypharma.info